TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02640755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]AZD2014
Description: Radiolabelled dual TORC1/TORC2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]AZD2014
Description: Radiolabelled dual TORC1/TORC2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]AZD2014
Description: Radiolabelled dual TORC1/TORC2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple dose AZD2014
Description: Dual TORC1/TORC2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple dose AZD2014
Description: Dual TORC1/TORC2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple dose AZD2014
Description: Dual TORC1/TORC2 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Hormonal Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Taxane
Study: NCT00380406

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Leuprolide acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide acetate
Study: NCT02864706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: All patients, independent of their initial randomization in the core study, were followed up as in one single group~Commercially available everolimus (Certican®), oral route, was used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
Study: NCT04567953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saliva collection
Description: Use Spectrum Solutions SDNA1000 or Orasure collection kit or dry tube to collect 1-3 ml of saliva
Study: NCT01678560

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring every 3 months by face-to-face visits
Description: These patients will be monitored on a 3-month, 6-month, 9-month and 12-month intervals with scheduling face-to-face visits. Adherence and efficacy data will only be assessed by the clinician at these intervals.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Frequent remote monitoring
Description: These patients will be monitored using wireless modems as the method to obtain adherence and efficacy and follow-up phone calls
Study: NCT04019236

Intervention type: OTHER
Group type: OTHER
Intervention: visual analogue scale (VAS),Respiratory distress observational scale (RDOS) and other Nursing care
Description: Distressed patient will be assessed by visual analogue scale(VAS) or respiratory distress observational scale.Nursing interventions will be done according to its causes as giving supplemental O2 therapy, pharmacologic therapy ,initiating positive pressure ventilation or change Ventilator settings (TV, PEEP, Inspiratory pressure ), Improve inspiratory muscle function by Nutrition, positioning or by minimizing use of steroids , clearing airway by Suctioning, Check O2 saturation level frequently and maintain O2 saturation between 95-100%, ,Raising the HOB (Head of the Bed), high Fowler's ,Give pain medications as prescribed or diuretics as ordered and If thick secretions increase oral fluids intake
Study: NCT03484689

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness-based cognitive therapy MBCT
Description: 8-week mindfulness-based cognitive therapy
Study: NCT00644813

Intervention type: OTHER
Intervention: Scapular with glenoid neck fractures
Study: NCT02048657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley Airway Stylet Tool

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: introducer-tool
Study: NCT00796224

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 60 mg/kg azithromycin ER
Description: subjects taken 60 mg/kg azithromycin ER

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30 mg/kg azithromycin IR
Description: subjects taken 30 mg/kg azithromycin IR (Immediate Release)
Study: NCT02777164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIRA device imaging
Description: MIRA Device imaging for adjunctive detection of breast cancer
Study: NCT03680105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RJX
Description: RJX is an IV infusion formulation. The appropriate RJX dose is calculated based on mL/kg. The administration dose is prepared by adding the appropriate RJX dose to 0.9% sterile saline such that a constant volume of 100 mL per IV infusion is obtained. Infusion time is 100 mL over 45 minutes (+/- 5 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RJX
Description: RJX is an IV infusion formulation. The appropriate RJX dose is calculated based on mL/kg. The administration dose is prepared by adding the appropriate RJX dose to 0.9% sterile saline such that a constant volume of 100 mL per IV infusion is obtained. Infusion time is 100 mL over 45 minutes (+/- 5 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RJX
Description: RJX is an IV infusion formulation. The appropriate RJX dose is calculated based on mL/kg. The administration dose is prepared by adding the appropriate RJX dose to 0.9% sterile saline such that a constant volume of 100 mL per IV infusion is obtained. Infusion time is 100 mL over 45 minutes (+/- 5 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RJX
Description: RJX is an IV infusion formulation. The appropriate RJX dose is calculated based on mL/kg. The administration dose is prepared by adding the appropriate RJX dose to 0.9% sterile saline such that a constant volume of 100 mL per IV infusion is obtained. Infusion time is 100 mL over 45 minutes (+/- 5 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RJX
Description: RJX is an IV infusion formulation. The appropriate RJX dose is calculated based on mL/kg. The administration dose is prepared by adding the appropriate RJX dose to 0.9% sterile saline such that a constant volume of 100 mL per IV infusion is obtained. Infusion time is 100 mL over 45 minutes (+/- 5 minutes).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RJX
Description: RJX is an IV infusion formulation. The appropriate RJX dose is calculated based on mL/kg. The administration dose is prepared by adding the appropriate RJX dose to 0.9% sterile saline such that a constant volume of 100 mL per IV infusion is obtained. Infusion time is 100 mL over 45 minutes (+/- 5 minutes).
Study: NCT00877734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: baclofen
Description: 10 mg Baclofen administered tid for 11 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo administered tid for 11 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRENDA counseling

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: BRENDA counseling
Study: NCT02422563

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hysterectomy
Description: radical hysterectomy

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Study: NCT00874224

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic left lateral hepatic sectionectomy
Description: laparoscopic left lateral hepatic sectionectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic left lateral hepatic sectionectomy
Description: laparoscopic left lateral hepatic sectionectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open left lateral hepatic sectionectomy
Description: open left lateral hepatic sectionectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open left lateral hepatic sectionectomy
Description: open left lateral hepatic sectionectomy
Study: NCT01547806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim will be administered as a single daily dose in a dose range of 10-16ug/kg/day subcutaneously for 5-7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Plerixafor will be given on day 4, 8-10 hours before the day 5 apheresis, dose calculated according to patient weight

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis
Description: The minimum cluster of differentiation 34 (CD34)+ cell dose that must be collected in order to proceed with a single autologous transplantation is 2 x 106 CD34+ cells/kg.
Study: NCT02001922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPD integrated care
Description: The intervention will target COPD integrated care, and include a combination of patient-related, professional and organizational elements. It will be centered on patients' needs and focus on self-management education, proactive follow-up (scheduled visits and/or phone contacts), team work, healthcare professionals' training, promotion of pulmonary rehabilitation, physical activity and smoking cessation.
Study: NCT01589692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Reduction and Internal Fixation
Description: Internal fixation with a volar locking plating system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External Fixation
Description: External Fixation with a bridging external fixator. Can be done with or without percutaneous pinning.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Pinning
Description: Pinning with any number of Kirschner wires

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed Reduction and casting
Description: Closed reduction and immobilization with a cast and/or splint
Study: NCT03527303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: 10 minute per day, 8 week digital meditation
Study: NCT03145506

Intervention type: DEVICE
Intervention: Multimodal Spectroscopy
Description: optical measurement of excised tissue
Study: NCT03964493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2092
Description: TNP-2092 100mg/vial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin 1g/vial
Study: NCT00591396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZIO-101 (Darinaparsin)
Description: Dose Escalation of ZIO-101 (Darinaparsin) given daily for five consecutive days to be repeated every 28 days for up to six months
Study: NCT03308266

Intervention type: DIAGNOSTIC_TEST
Intervention: electromyography

Intervention type: DIAGNOSTIC_TEST
Intervention: electromyography
Study: NCT03713775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal Replacement Weight Loss Programme
Description: The study intervention will be the referral to a commercial provider (CP) offering a Meal Replacement Programme. Briefly, participants will be referred to a nominated CP local counsellor who will set regular appointments during a period of 32-to-36 weeks to provide behavioural support, weight monitoring, and deliver formula meals. All counselors delivering the programme will receive, beyond their routine training and accreditation, specific information related to this study before being allocated patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants randomised to the control group will receive best usual care, consisting of a one-off face-to-face consultation on weight loss with a nurse at baseline (\~15 min), together with supporting written information.
Study: NCT04436887

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positioning of polypropylene strips for prophylactic purposes in closing the middle laparotomies to prevent the incisional hernia
Description: Sub-lay mesh supported closure A 4 cm space is created between posterior rectus sheath and rectus muscle, widening 2 cm at each side of midline. Both posterior rectus sheath edges are sutured using a running slowly absorbable suture. Above arcuate line, posterior layer was performed suturing peritoneum and posterior rectus sheath; below arcuate line, posterior layer was performed suturing peritoneum and trasversalis fascia. Anterior layer was performed suturing anterior rectus sheath. A suture length to wound length ratio of 4:1 is recommended. A 4-cm Parietex Progrip Mesh strip was placed between the posterior rectus sheath and rectus muscle with an overlap of at least 2 cm at each side, suture less. In laparotomies \>20 cm two stripes of 15 cm each were designed. The midline anterior rectus sheath was closed using a running slowly absorbable suture, covering the mesh. A suture length to wound length ratio of 4:1 is recommended.
Study: NCT05430984

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic TAPP inguinal hernia repair
Description: Isolation of preperitoneal space will be accomplished to guarantee the mesh flattening with the medial border at the pubic symphysis, the lateral border at the psoas major and anterior superior iliac spine, superior border at least 3 cm above the conjoined tendon, medial inferior border 3 cm below the pectineal ligament, and lateral inferior border to permit perietalization of the spermatic cord (6-8 cm isolation of the hernia sac and spermatic cord).~For the mesh fixation group, the mesh will be fixed to the abdominal wall using suture, spiral tacks, whereas for the non-fixation group it will be left as it is and the operation will be concluded. A mesh measuring 15x10cm is placed in the preperitoneal space and fixed using limited numbers of tacks or suture. In some cases, based on body habitus, a slightly smaller mesh could be used. The peritoneum will be closed over the mesh.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic TAPP inguinal hernia repair
Description: Isolation of preperitoneal space will be accomplished to guarantee the mesh flattening with the medial border at the pubic symphysis, the lateral border at the psoas major and anterior superior iliac spine, superior border at least 3 cm above the conjoined tendon, medial inferior border 3 cm below the pectineal ligament, and lateral inferior border to permit perietalization of the spermatic cord (6-8 cm isolation of the hernia sac and spermatic cord).~For the mesh fixation group, the mesh will be fixed to the abdominal wall using suture, spiral tacks, whereas for the non-fixation group it will be left as it is and the operation will be concluded. A mesh measuring 15x10cm is placed in the preperitoneal space and fixed using limited numbers of tacks or suture. In some cases, based on body habitus, a slightly smaller mesh could be used. The peritoneum will be closed over the mesh.
Study: NCT03453801

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone®
Description: Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine): The pediatric dose (6-35 months) will be supplied in a prefilled, single dose syringe, 0.25 mL (no preservative). Each 0.5 mL dose of Fluzone® Quadrivalent (36 months-adult) will be supplied in a prefilled, single dose syringe, 0.5 mL (no preservative). Both formulations given IM.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone®
Description: Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine): The pediatric dose (6-35 months) will be supplied in a prefilled, single dose syringe, 0.25 mL (no preservative). Each 0.5 mL dose of Fluzone® Quadrivalent (36 months-adult) will be supplied in a prefilled, single dose syringe, 0.5 mL (no preservative). Both formulations given IM.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone®
Description: Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine): The pediatric dose (6-35 months) will be supplied in a prefilled, single dose syringe, 0.25 mL (no preservative). Each 0.5 mL dose of Fluzone® Quadrivalent (36 months-adult) will be supplied in a prefilled, single dose syringe, 0.5 mL (no preservative). Both formulations given IM.
Study: NCT03405974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin (acetylsalicylic acid)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03966664

Intervention type: DIAGNOSTIC_TEST
Intervention: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.
Description: Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.

Intervention type: DIAGNOSTIC_TEST
Intervention: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.
Description: Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.

Intervention type: DIAGNOSTIC_TEST
Intervention: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in isolated plasma.
Description: Collection of a venous blood sample, centrifugation in order to harvest isolated plasma and performance of in-vitro tonometry in order to assess Ka and Atot.

Intervention type: DIAGNOSTIC_TEST
Intervention: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood
Description: Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.

Intervention type: DIAGNOSTIC_TEST
Intervention: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood
Description: Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.

Intervention type: DIAGNOSTIC_TEST
Intervention: In vitro determination the dissociation constant (Ka) and total amount of non-volatile buffers (Atot) in whole blood
Description: Collection of a venous blood sample and performance of in-vitro tonometry in order to assess Ka and Atot.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomolecular analysis of plasma proteins.
Description: Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomolecular analysis of plasma proteins.
Description: Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomolecular analysis of plasma proteins.
Description: Bidimensional electrophoresis, determination of oxidized albumin fraction, characterization of altered ligand binding properties of plasma albumin.
Study: NCT01687049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Red yeast rice
Study: NCT03167827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isoflavone
Description: Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Daily supplementation in 1 capsule per day containing starch of corn.
Study: NCT00821054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Treatment A: one dose of 1250mg lapatinib 1 hour before starting a low-fat breakfast; Treatment B: one dose of 1250mg lapatinib 1 hour after finishing a low fat breakfast; or Treatment C: one dose of 1250mg lapatinib 1 hour after finishing a high-fat breakfast.
Study: NCT03453801

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist®
Description: FluMist® Quadrivalent: live, attenuated influenza virus vaccine quadrivalent, given by intranasal spray

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist®
Description: FluMist® Quadrivalent: live, attenuated influenza virus vaccine quadrivalent, given by intranasal spray
Study: NCT00040768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study: NCT03869086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Freeze dried blueberry powder
Description: 36 g of freeze-dried blueberry powder to be mixed with milk and served together with an energy-dense meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Freeze dried blueberry powder
Description: 36 g of freeze-dried blueberry powder to be mixed with milk and served together with an energy-dense meal.
Study: NCT03869086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anthocyanin free, sugar-matched placebo
Description: 36 g of isocaloric placebo, matched for sugars to be mixed with milk and served together with an energy-dense meal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anthocyanin free, sugar-matched placebo
Description: 36 g of isocaloric placebo, matched for sugars to be mixed with milk and served together with an energy-dense meal.
Study: NCT04673682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D309
Description: D309(Testosterone) 1 vial, Once, IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D309
Description: D309(Testosterone) 1 vial, Once, IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-845
Description: CKD-845(Testosterone) 1 vial, Once, IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-845
Description: CKD-845(Testosterone) 1 vial, Once, IM injection
Study: NCT01170013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-up
Description: Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent psychoeducation
Description: Two sessions of psychoeducation for parents regarding adolescent risk behaviors. especially substance use